[
  {
    "pdf": "scihub_bloodadvances.2019030924.pdf_3",
    "image_path": "scihub_bloodadvances.2019030924.pdf_3.pdf_0.jpg",
    "page_idx": 0,
    "category_type": "figure_caption",
    "bbox_norm": null,
    "text": "**Table 2.** Risk for developing second primary infection-related solid tumors among adult 1-y NHL survivors, 17 SEER registry areas, 2000 to 2014",
    "html": ""
  },
  {
    "pdf": "scihub_bloodadvances.2019030924.pdf_3",
    "image_path": "scihub_bloodadvances.2019030924.pdf_3.pdf_0.jpg",
    "page_idx": 0,
    "category_type": "table",
    "bbox_norm": null,
    "text": "",
    "html": "<table><thead><tr><th rowspan=\"3\">Second primary<br>malignancy site</th><th colspan=\"9\">First primary NHL subtype</th><th rowspan=\"3\">P<sub>heterogeneity</sub><sup>*</sup></th></tr><tr><th colspan=\"3\">CLL/SLL</th><th colspan=\"3\">DLBCL</th><th colspan=\"3\">FL</th><th colspan=\"3\">MZL</th></tr><tr><th>Obs</th><th>SIR†</th><th>95% CI†</th><th>Obs</th><th>SIR†</th><th>95% CI†</th><th>Obs</th><th>SIR†</th><th>95% CI†</th><th>Obs</th><th>SIR†</th><th>95% CI†</th></tr></thead><tbody><tr><td>Oropharynx/tonsil</td><td>30</td><td>1.08</td><td>0.73-1.54</td><td>22</td><td>1.04</td><td>0.65-1.58</td><td>18</td><td>1.00</td><td>0.59-1.58</td><td>7</td><td>0.96</td><td>0.39-1.98</td><td>.99</td></tr><tr><td>Stomach</td><td>39</td><td>0.70‡</td><td>0.50-0.96</td><td>62</td><td>1.51‡</td><td>1.16-1.94</td><td>26</td><td>0.81</td><td>0.53-1.19</td><td>44</td><td>2.78‡</td><td>2.02-3.74</td><td>&lt;.01</td></tr><tr><td>Anus</td><td>16</td><td>1.57</td><td>0.90-2.55</td><td>31</td><td>3.71‡</td><td>2.52-5.27</td><td>5</td><td>0.67</td><td>0.22-1.56</td><td>8</td><td>2.36‡</td><td>1.02-4.64</td><td>&lt;.01</td></tr><tr><td>Liver</td><td>54</td><td>1.04</td><td>0.78-1.36</td><td>76</td><td>1.85‡</td><td>1.46-2.31</td><td>32</td><td>0.98</td><td>0.67-1.39</td><td>30</td><td>1.98‡</td><td>1.34-2.83</td><td>&lt;.01</td></tr><tr><td>Cervix uteri</td><td>7</td><td>0.78</td><td>0.31-1.61</td><td>9</td><td>0.89</td><td>0.41-1.69</td><td>8</td><td>0.87</td><td>0.38-1.72</td><td>&lt;5</td><td>0.68</td><td>0.14-1.98</td><td>.98</td></tr></tbody></table>"
  },
  {
    "pdf": "scihub_bloodadvances.2019030924.pdf_3",
    "image_path": "scihub_bloodadvances.2019030924.pdf_3.pdf_0.jpg",
    "page_idx": 0,
    "category_type": "figure",
    "bbox_norm": null,
    "text": "",
    "html": ""
  },
  {
    "pdf": "scihub_bloodadvances.2019030924.pdf_3",
    "image_path": "scihub_bloodadvances.2019030924.pdf_3.pdf_0.jpg",
    "page_idx": 0,
    "category_type": "figure_caption",
    "bbox_norm": null,
    "text": "**Figure 1.** Risk for developing second primary stomach cancer among adult 1-year DLBCL and MZL survivors by site of DLBCL or MZL, 2000 to 2014. SIRs and exact Poisson-based 95% CIs compared the number of observed cases with that expected in the general population (additional details provided in \"Methods\"). *P* values to test differences in the SIRs were computed using a likelihood ratio test derived from Poisson regression models stratified by age at first primary NHL, sex, and latency, with the log of the expected numbers of cases included as an offset. All statistical tests were 2 sided. Created using GraphPad Prism (version 7; La Jolla, CA).",
    "html": ""
  },
  {
    "pdf": "scihub_bloodadvances.2019030924.pdf_3",
    "image_path": "scihub_bloodadvances.2019030924.pdf_3.pdf_0.jpg",
    "page_idx": 0,
    "category_type": "figure",
    "bbox_norm": null,
    "text": "",
    "html": ""
  }
]